Abbott Laboratories (ABT) Stock Forecast & Price Target

Compare

8,452 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ABT Analyst Ratings

Strong Buy

17 Buy

4 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Abbott

Laboratories

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ABT Stock 12 Month Forecast

Average Price Target

$143.26

▲(6.61%Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Abbott Laboratories in the last 3 months. The average price target is $143.26 with a high forecast of $159.00 and a low forecast of $127.00. The average price target represents a 6.61% change from the last price of $134.38.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"99":"$99","160":"$160","114.25":"$114.3","129.5":"$129.5","144.75":"$144.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":159,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$159.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":143.26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$143.26</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":127,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$127.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[99,114.25,129.5,144.75,160],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,133.57,135.52615384615385,137.4823076923077,139.43846153846152,141.39461538461538,143.35076923076923,145.30692307692308,147.2630769230769,149.21923076923076,151.17538461538462,153.13153846153847,155.0876923076923,157.04384615384615,{"y":159,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,133.57,134.3153846153846,135.0607692307692,135.80615384615385,136.55153846153846,137.29692307692306,138.04230769230767,138.7876923076923,139.53307692307692,140.27846153846153,141.02384615384614,141.76923076923077,142.51461538461538,{"y":143.26,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,133.57,133.06461538461537,132.55923076923077,132.05384615384614,131.54846153846154,131.0430769230769,130.5376923076923,130.03230769230768,129.52692307692308,129.02153846153846,128.51615384615386,128.01076923076923,127.50538461538461,{"y":127,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":100.18,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.17,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.56,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.63,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.92,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.44,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":115.66,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.34,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.37,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.08,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.88,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.57,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$159.00

Average Price Target$143.26

Lowest Price Target$127.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$153

Buy

13.86%

Upside

Reiterated

05/16/25

Abbott Laboratories receives a solid score due to its strong financial performance and positive earnings call highlights, bolstered by strategic investments and growth in medical devices and nutrition segments. Despite some challenges, such as tariffs and declining diagnostics sales, the company's effective management and strategic initiatives offer a promising outlook. Technical indicators support a positive trend, while valuation remains fair.

Josh JenningsTD Cowen

TD Cowen

$145

Buy

7.90%

Upside

Reiterated

06/29/25

TD Cowen Reaffirms Their Buy Rating on Abbott Laboratories (ABT)

Larry BiegelsenWells Fargo

Wells Fargo

$155→$147

Buy

9.39%

Upside

Reiterated

06/27/25

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND), Abbott Laboratories (NYSE: ABT) and I-MAB (NASDAQ: IMAB)

Travis SteedBank of America Securities

Bank of America Securities

$150

Buy

11.62%

Upside

Reiterated

06/24/25

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Capricor Therapeutics (NASDAQ: CAPR) and Abbott Laboratories (NYSE: ABT)

Joanne WuenschCiti

Citi

―

Buy

―

Reiterated

06/23/25

Citi Remains a Buy on Abbott Laboratories (ABT)

Suraj KaliaOppenheimer

Oppenheimer

$140

Buy

4.18%

Upside

Reiterated

06/18/25

Abbott Laboratories (ABT) Gets a Buy from Oppenheimer

Mike KratkyLeerink Partners

Leerink Partners

$143

Hold

6.41%

Upside

Initiated

06/16/25

Abbott Laboratories (ABT) Receives a Hold from Leerink Partners

Rick WiseStifel Nicolaus

Stifel Nicolaus

$135→$145

Buy

7.90%

Upside

Reiterated

05/27/25

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Pfizer (NYSE: PFE)

Matt MiksicBarclays

Barclays

$159

Buy

18.32%

Upside

Reiterated

05/20/25

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Alcon (NYSE: ALC)

David ToungArgus Research

Argus Research

$150

Buy

11.62%

Upside

Reiterated

04/21/25

Argus Research Remains a Buy on Abbott Laboratories (ABT)

Jayson BedfordRaymond James

Raymond James

$132→$142

Buy

5.67%

Upside

Reiterated

04/17/25

Abbott price target raised to $142 from $132 at Raymond JamesAbbott price target raised to $142 from $132 at Raymond James

Adam MaederPiper Sandler

Piper Sandler

$133→$145

Buy

7.90%

Upside

Reiterated

04/17/25

Abbott price target raised to $145 from $133 at Piper SandlerAbbott price target raised to $145 from $133 at Piper Sandler

Margaret KaczorWilliam Blair

William Blair

―

Buy

―

Reiterated

04/17/25

Abbott Laboratories: Strong Performance and Strategic Positioning Drive Buy Rating

Danielle AntalffyUBS

UBS

$148

Buy

10.14%

Upside

Reiterated

04/17/25

UBS reiterates Buy Rating on Abbott Labs (ABT)UBS analyst Danielle Antalffy reiterated a Buy rating and $148.00 price target on Abbott Labs (NYSE: ABT).

Patrick WoodMorgan Stanley

Morgan Stanley

$117→$127

Hold

-5.49%

Downside

Reiterated

04/17/25

Abbott price target raised to $127 from $117 at Morgan StanleyAbbott price target raised to $127 from $117 at Morgan Stanley

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$153

Buy

13.86%

Upside

Reiterated

05/16/25

Josh JenningsTD Cowen

TD Cowen

$145

Buy

7.90%

Upside

Reiterated

06/29/25

TD Cowen Reaffirms Their Buy Rating on Abbott Laboratories (ABT)

Larry BiegelsenWells Fargo

Wells Fargo

$155→$147

Buy

9.39%

Upside

Reiterated

06/27/25

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND), Abbott Laboratories (NYSE: ABT) and I-MAB (NASDAQ: IMAB)

Travis SteedBank of America Securities

Bank of America Securities

$150

Buy

11.62%

Upside

Reiterated

06/24/25

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX), Capricor Therapeutics (NASDAQ: CAPR) and Abbott Laboratories (NYSE: ABT)

Joanne WuenschCiti

Citi

―

Buy

―

Reiterated

06/23/25

Citi Remains a Buy on Abbott Laboratories (ABT)

Suraj KaliaOppenheimer

Oppenheimer

$140

Buy

4.18%

Upside

Reiterated

06/18/25

Abbott Laboratories (ABT) Gets a Buy from Oppenheimer

Mike KratkyLeerink Partners

Leerink Partners

$143

Hold

6.41%

Upside

Initiated

06/16/25

Abbott Laboratories (ABT) Receives a Hold from Leerink Partners

Rick WiseStifel Nicolaus

Stifel Nicolaus

$135→$145

Buy

7.90%

Upside

Reiterated

05/27/25

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Pfizer (NYSE: PFE)

Matt MiksicBarclays

Barclays

$159

Buy

18.32%

Upside

Reiterated

05/20/25

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Alcon (NYSE: ALC)

David ToungArgus Research

Argus Research

$150

Buy

11.62%

Upside

Reiterated

04/21/25

Argus Research Remains a Buy on Abbott Laboratories (ABT)

Jayson BedfordRaymond James

Raymond James

$132→$142

Buy

5.67%

Upside

Reiterated

04/17/25

Abbott price target raised to $142 from $132 at Raymond JamesAbbott price target raised to $142 from $132 at Raymond James

Adam MaederPiper Sandler

Piper Sandler

$133→$145

Buy

7.90%

Upside

Reiterated

04/17/25

Abbott price target raised to $145 from $133 at Piper SandlerAbbott price target raised to $145 from $133 at Piper Sandler

Margaret KaczorWilliam Blair

William Blair

―

Buy

―

Reiterated

04/17/25

Abbott Laboratories: Strong Performance and Strategic Positioning Drive Buy Rating

Danielle AntalffyUBS

UBS

$148

Buy

10.14%

Upside

Reiterated

04/17/25

UBS reiterates Buy Rating on Abbott Labs (ABT)UBS analyst Danielle Antalffy reiterated a Buy rating and $148.00 price target on Abbott Labs (NYSE: ABT).

Patrick WoodMorgan Stanley

Morgan Stanley

$117→$127

Hold

-5.49%

Downside

Reiterated

04/17/25

Abbott price target raised to $127 from $117 at Morgan StanleyAbbott price target raised to $127 from $117 at Morgan Stanley

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Abbott Laboratories

1 Month

xxx

Success Rate

27/37 ratings generated profit

Average Return

+2.99%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 72.97% of your transactions generating a profit, with an average return of +2.99% per trade.

3 Months

xxx

Success Rate

23/27 ratings generated profit

Average Return

+5.80%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 85.19% of your transactions generating a profit, with an average return of +5.80% per trade.

1 Year

Rick WiseStifel Nicolaus

Success Rate

24/25 ratings generated profit

Average Return

+18.68%

reiterated a buy rating last month

Copying Rick Wise's trades and holding each position for 1 Year would result in 96.00% of your transactions generating a profit, with an average return of +18.68% per trade.

2 Years

xxx

Success Rate

23/27 ratings generated profit

Average Return

+19.10%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 85.19% of your transactions generating a profit, with an average return of +19.10% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABT Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ABT has received 41 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. ABT average Analyst price target in the past 3 months is 143.26.

Each month's total comprises the sum of three months' worth of ratings.

ABT Financial Forecast

ABT Earnings Forecast

Next quarter’s earnings estimate for ABT is $1.25 with a range of $1.23 to $1.28. The previous quarter’s EPS was $1.09. ABT beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.13% of the time in the same period. In the last calendar year ABT has Outperformed its overall industry.

ABT Sales Forecast

Next quarter’s sales forecast for ABT is $11.07B with a range of $10.99B to $11.27B. The previous quarter’s sales results were $10.36B. ABT beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.44% of the time in the same period. In the last calendar year ABT has Outperformed its overall industry.

ABT Stock Forecast FAQ

What is ABT’s average 12-month price target, according to analysts?

Based on analyst ratings, Abbott Laboratories’s 12-month average price target is 143.26.

What is ABT’s upside potential, based on the analysts’ average price target?

Abbott Laboratories has 6.61% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ABT a Buy, Sell or Hold?

Abbott Laboratories has a consensus rating of Strong Buy which is based on 17 buy ratings, 4 hold ratings and 0 sell ratings.

What is Abbott Laboratories’s price target?

The average price target for Abbott Laboratories is 143.26. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $159.00 ,the lowest forecast is $127.00. The average price target represents 6.61% Increase from the current price of $134.38.

What do analysts say about Abbott Laboratories?

Abbott Laboratories’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of ABT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Abbott Laboratories (ABT) Stock Forecast & Price Target

ABT Analyst Ratings

ABT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Abbott Laboratories

ABT Analyst Recommendation Trends

ABT Financial Forecast

ABT Earnings Forecast

ABT Sales Forecast

ABT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts